G.A. Bezerra

This paper evaluates the efficacy of multimeric bicyclic peptides as antiviral agents in preclinical SARS-CoV-2 models, showing significant reduction in viral burden across multiple therapeutic settings.

This paper develops synthetic peptides that activate NK cells to kill tumor cells by binding to NKp46 and tumor antigens, leading to cytokine secretion and enhanced anti-tumor immunity.